Natco Pharma reports 61% drop in Q2 consolidated net profit

The company has reported 71.41% drop in its net profit at Rs 143.20 crore for the quarter ended September 30, 2026 as compared to Rs 500.90 crore for the same quarter in the previous year. The total income of the company has decreased by 34.09% at Rs 894.80 crore for Q2FY27 as compared to Rs 1,357.60 crore for the corresponding quarter of the previous year. On consolidated basis, the company has reported 60.92% drop in its net profit at Rs 202.60 crore for the quarter ended September 30, 2026 as compared to Rs 518.40 crore for the same quarter in the previous year. The total income of the company decreased by 30.32% at Rs 1,019.40 crore for Q2FY27 as compared to Rs 1,463.00 crore for the corresponding quarter previous year. Key Factors : - Lower Lenalidomide revenue heavily dragged down the top line. However, growth in the base business and a sequential recovery in international formulations—from Rs. 477.1 crore in Q1 FY27 to Rs. 668.4 crore in Q2 FY27—helped offset the decline. Outlook: - Management is completing an internal semaglutide cartridge manufacturing line expected to come online in FY28. While the domestic Indian semaglutide market remains margin-thin due to heavy competition, launches in select international markets (such as Canada and Brazil) are slated to drive FY28 growth. Disclosure : I do not hold any position in the mentioned stock. This is only for educational purpose. NATCOPHARM